Innoviva, Inc.
(NASDAQ : INVA)

( )
INVA After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
VRXValeant Pharmaceuticals International, Inc.
2.19%18.6714.1%$206.14m
SHPGShire PLC Sponsored ADR
0.82%127.080.4%$198.44m
SAGESAGE Therapeutics, Inc.
5.63%164.159.8%$121.02m
PRGOPerrigo Co. Plc
1.32%88.226.6%$81.44m
ICPTIntercept Pharmaceuticals, Inc.
4.18%62.0422.0%$66.78m
UTHRUnited Therapeutics Corporation
0.42%118.0414.5%$58.71m
JAZZJazz Pharmaceuticals Plc
2.11%147.462.2%$53.79m
MNKMallinckrodt Plc
1.51%16.1618.5%$51.55m
CTLTCatalent Inc
0.94%42.822.6%$49.63m
GWPHGW Pharmaceuticals PLC Sponsored ADR
-1.67%115.317.6%$48.13m
MDCOMedicines Company
4.16%31.0722.1%$47.22m
PBHPrestige Brands Holdings, Inc.
0.46%35.163.8%$42.64m
ICLRICON Plc
3.24%114.894.1%$42.32m
CORTCorcept Therapeutics Incorporated.
2.42%16.485.5%$42.03m
PTLAPortola Pharmaceuticals, Inc.
1.78%45.827.8%$40.16m

Company Profile

Innoviva, Inc. engages in the development, commercialization, and financial management of bio-pharmaceuticals. Its portfolio includes Relvar Breo Ellipta, which is a once-daily combination medicine consisting of a long-acting beta2 agonist, vilanterol, and an inhaled corticosteroid, fluticasone furoate; and Anoro Ellipta, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, LABA, VI. The company was founded by P. Roy Vagelos, Mathai Mammen, and George M. Whitesides in November 1996 and is headquartered in Brisbane, CA.